Advertisement

Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018

  • Yara-Natalie AboEmail author
  • Erika Refsum
  • Nicola Mackie
  • Hermione Lyall
  • Gareth Tudor-Williams
  • Caroline Foster
Short Communication
  • 45 Downloads

Abstract

Background and Objective

Integrase strand transfer inhibitors (INSTIs) have become the preferred first-line antiretroviral therapy in adults. There is paucity of published data on their use in children outside of clinical trials, particularly long-term safety and tolerability. This study aimed to describe INSTI use including the number of, and reasons for INSTI discontinuation.

Methods

We conducted a retrospective cohort analysis by database and electronic record review of children aged under 18 years with perinatally acquired human immunodeficiency virus who started INSTI-based antiretroviral therapy between May 2009 and March 2018, in a single tertiary centre.

Results

Fifty-six INSTI-based regimens were prescribed in 54 children, 64.9% from 2015 onwards. Twenty-one of 56 (37.5%) regimens commenced with raltegravir, 29 (51.8%) with dolutegravir and six (10.7%) with elvitegravir. The median age at the start of treatment was 15 years (interquartile range 13.5–16.4) with a median duration of INSTI-antiretroviral therapy of 1.65 years (range 0.01–8.8). Twenty-four children had a detectable viral load at the start INSTI therapy; 20 (83%) achieving viral suppression in a median of 26 days (interquartile range 19.5–34.5). There were 26 discontinuations of INSTI-based antiretroviral therapy after a median of 183 days; 9/26 because of adverse events. Four of nine adverse events were attributed to INSTI use, all in patients taking dolutegravir and the adverse events were neuropsychiatric and gastrointestinal in nature.

Conclusions

INSTI-based regimens were generally efficacious and well tolerated in this paediatric cohort, with 4/26 discontinuations due to INSTI-attributed adverse events. Further post-marketing surveillance of INSTI use in children is warranted.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were received for the conduct of this study. The study was carried out as part of routine work.

Conflict of interest

Yara-Natalie Abo, Erika Refsum, Nicola Mackie, Hermione Lyall, Gareth Tudor-Williams and Caroline Foster have no conflicts of interest that are directly relevant to the content of this study.

Ethics approval

The study was registered with the hospital clinical governance department, fulfilling research ethical requirements.

Informed consent

No informed consent was required as only de-identified data were collected from patient records and no procedures or interventions were performed.

References

  1. 1.
    Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRefGoogle Scholar
  2. 2.
    UNICEF. Adolescents living with HIV: developing and strengthening care and support services. Geneva: UNICEF Regional Office for Central and Eastern Europe and the Commonwealth of Independent States (CEECIS); 2016. https://www.unicef.org/eca/sites/unicef.org.eca/files/2017-10/Adolescents_Living_with_HIV.pdf. Accessed 3 Jan 2018.
  3. 3.
    Slogrove AL, Mahy M, Armstrong A, Davies MA. Living and dying to be counted: what we know about the global adolescent HIV epidemic. J Int AIDS Soc. 2017;20(Suppl. 3):21520.Google Scholar
  4. 4.
    Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://aidsinfo.nih.gov/con-tentles/lvguidelines/pediatricguidelines.pdf. Accessed 2 Jan 2018.
  5. 5.
    Viani RM, Alvero C, Fenton T, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. Pediatr Infect Dis J. 2015;34(11):1207–13.  https://doi.org/10.1097/INF.0000000000000848.CrossRefGoogle Scholar
  6. 6.
    World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd edn. 2016. http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence = 1. Accessed 2 Apr 2018.
  7. 7.
    Le Doare K, Mackie NE, Kaye S, Bamford A, et al. Virtual support for paediatric HIV treatment decision making. Arch Dis Child. 2015;100(6):527–31.CrossRefGoogle Scholar
  8. 8.
    Peñafiel J, De Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017;72(6):1752–9.CrossRefGoogle Scholar
  9. 9.
    de Boer MGJ, van den Berk GEL, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016;30(18):2831–4.CrossRefGoogle Scholar
  10. 10.
    Hoffman C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63.CrossRefGoogle Scholar
  11. 11.
    National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 2 Apr 2018.
  12. 12.
    Sabin C, Smith C, Delpech V, et al. The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Med. 2009;10:35–43.CrossRefGoogle Scholar
  13. 13.
    Messiaen P, Wensing AMJ, Fun A, et al. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS One. 2013;8(1):e52562.CrossRefGoogle Scholar
  14. 14.
    Kirby C, Ovens K, Shaw M, et al. Adverse events of dolutegravir may be higher in real world settings [BHIVA abstract no. P26]. HIV Med. 2016;17(Suppl. 1):22.Google Scholar
  15. 15.
    Cunningham L, Clarke F, Healy B, et al. Dolutegravir use in naıve and experienced patients in 2 linked clinical settings: a review of indications, outcomes and patient experience [BHIVA abstract P36]. HIV Med. 2016;17(Suppl. 1):26.Google Scholar
  16. 16.
    Negedu O, Naous N, Weston R, et al. Retrospective review of real life patient experiences with dolutegravir; virological suppression, immunological recovery and adverse events [BHIVA abstract P28]. HIV Med. 2016;17(Suppl. 1):23.Google Scholar
  17. 17.
    Simons R, de Ruiter A, Kulasegaram R. Dolutegravir use in 181 patients, 54 women and 9 pregnancies: a real life experience [BHIVA abstract P9]. HIV Med. 2016;17(Suppl. 1):17.Google Scholar
  18. 18.
    Postel N, Mueller M, Wyen C, et al. The DOL-ART cohort: providing evidence from real-world data use of dolutegravir-based regimens in routine clinical care in Germany [HIV Glasgow abstract P133]. J Int AIDS Soc. 2016;19(Suppl. 7):105.Google Scholar
  19. 19.
    Fernandez C, Kirsten M, Thomson-Glover R, et al. Adverse events and discontinuation of dolutegravir-based therapy in naive and experienced HIV patients: tertiary HIV centre experience [HIV Glasgow abstract P212]. J Int AIDS Soc. 2016;19(Suppl. 7):156–7.Google Scholar
  20. 20.
    Wiznia A, Alvero C, Fenton T, et al. IMPAACT 1093: dolutegravir in 6- to 12-year-old HIV-infected children: 48-week results. In: 23rd Conference on retroviruses and opportunistic infections (CROI); 22–25 Feb 2016, Boston MA.Google Scholar
  21. 21.
    Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis. 2014;58(3):413–22.CrossRefGoogle Scholar
  22. 22.
    Nachman S, Alvero C, Acosta EP, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. J Pediatr Infect Dis Soc. 2015;4(4):e76–83.CrossRefGoogle Scholar
  23. 23.
    Monteiro P, Iñaki P, Judit P, et al. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. J Antimicrob Chemother. 2013;68(2):404–8.CrossRefGoogle Scholar
  24. 24.
    Briand C, Dollfus C, Faye A, et al. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study. J Antimicrob Chemother. 2017;72(3):837–43.Google Scholar
  25. 25.
    Gaur A, Cotton M, Radriguez C, et al. Bictegravir/FTC/TAF single-tablet regimen in adolescents and children: week 48 results. In: 26th Conference on retroviruses and opportunistic infections (CROI); 4–7 Mar 2019, Boston (MA).Google Scholar
  26. 26.
    Astuti N, Maggiolo F. Single-tablet regimens in HIV therapy. Infect Dis Ther. 2014;3:1–17.CrossRefGoogle Scholar
  27. 27.
    UN Aids 2018. Undetectable = Untransmittable. Public health and HIV viral load suppression. http://www.unaids.org/en/resources/presscentre/featurestories/2018/july/undetectable-untransmittable. Accessed 26 Feb 2019.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Imperial College Healthcare NHS TrustLondonUK
  2. 2.Imperial College LondonLondonUK
  3. 3.St Mary’s HospitalLondonUK

Personalised recommendations